You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK)中期純利同比大增106.8% 大輸液市場份額持續提升、市場龍頭地位獲鞏固
格隆匯 08-29 12:14

格隆匯8月29日丨石四藥集團(02005.HK)公佈2022年中期業績,期內集團實現銷售收入34.05億港元,同比增長39.4%;公司股權持有人應占溢利5.70億港元,同比增長106.8%;每股基本盈利0.1906港元,同比增長109.5%;宣派中期股息每股6港仙,同比增長20%。

注射劑產銷繼續保持穩中有升勢頭,治療性重點產品佔比呈現新增長。疫情常態化下,國內醫藥市場剛性需求穩定,集團大輸液市場份額持續提升,市場龍頭地位得到持續鞏固。2022年上半年,輸液銷量約7.54億瓶(袋),同比增長約19.3%,輸液銷售額實現約18.34億港元,同比增長約20%。其中,重點輸液產品實現銷量約1.27億瓶(袋),同比增長約41%,當中甘露醇銷售量約1698萬瓶(袋),同比增長約36%;鹽酸氨溴索氯化鈉注射液銷售量約188萬瓶,同比增長約566%;鹽酸莫西沙星銷售量約196萬袋,同比增長約218%;腹膜透析液產品銷量約156萬袋,同比增長約233%;乳酸環丙沙星銷售量約708萬瓶(袋),同比增長約183%;氟康唑銷售量約83萬袋,同比增長約797%。

安瓿產品市場表現突出,成為集團注射液板塊發展的新支點。上半年,主要產品鹽酸倍他司汀注射液銷量1294萬支,同比增長約16.7%。集團在加快鹽酸氨溴索、多索茶礆、鹽酸羅哌卡因等國家集採中標品種銷售的同時,着力推動鹽酸溴己新、硫酸特布他林霧化吸入用溶液、右美託咪定等安瓿新產品的市場推廣,收到預期效果。上半年,集團安瓿產品銷量約6827萬支,同比增長約36.9%,銷售收入5.11億港元,保持良好增長勢頭,成為發展新動能。此外,集團首個眼用液體制劑品種鹽酸莫西沙星滴眼液獲批上市,填補集團該製劑空白。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account